Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.
The researchers found that 6.5% of adults experienced cost burdens and 3.5% had CCBs during year one; 17.4% and 9.9%, respectively, experienced these outcomes at least once over 4 years. Overall, 24.7 ...
Receipt of educational leaflet also reduces misperception of asymptomatic bacteriuria as urinary tract infection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback